Rizafilm
Product Images NDC 50090-8038

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rizafilm (NDC 50090-8038). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Fig1)

A line graph depicting the estimated probability of response over 2 hours post-dose for placebo, rizatriptan benzoate 5mg, and rizatriptan benzoate 10mg. The y-axis shows probability of response from 0% to 100%, and the x-axis shows time in hours from 0 to 2. Both doses of rizatriptan show higher response probabilities than placebo, increasing over time.*

FDA Label Image

Figure2 (Fig2)

A line graph showing the estimated probability of remediation or rescue over 24 hours post-dose for placebo, rizatriptan benzoate 5 mg, and rizatriptan benzoate 10 mg. The x-axis represents hours post-dose, and the y-axis shows probability percentage from 0% to 100%, with three curves demonstrating the comparative probabilities over time.*

FDA Label Image

Figure 3 (Fig3)

A line graph showing the estimated probability of response over two hours post-dose for placebo, rizatriptan benzoate 5 mg, and rizatriptan benzoate 10 mg. The vertical axis represents the probability in percentage, while the horizontal axis shows hours after dosing. The 10 mg dose demonstrates the highest probability of response, followed by 5 mg and placebo.*

FDA Label Image

Figure 4 (Fig4)

A line graph showing the estimated probability of remediation or rescue over 24 hours post-dose for placebo and two doses of rizatriptan benzoate (5 mg and 10 mg). The x-axis represents hours post-dose, and the y-axis shows the estimated probability percentage, with three trend lines depicting placebo, 5 mg, and 10 mg doses respectively.*

FDA Label Image

Figure5 (Fig5)

A line graph comparing the percentage (with 95% confidence intervals) over time in hours after a Stage 2 dose of Rizatriptan Benzoate versus placebo. The x-axis shows hours post dose (0.5 to 2 hours), and the y-axis shows the percent response. Rizatriptan Benzoate shows a higher percentage response than placebo, with both increasing over time.*

FDA Label Image

Label Image (Lbl500908038)

RIZAFILM 10 mg oral film label showing the active ingredient rizatriptan benzoate. The package contains 3 oral films, each film delivering 10 mg of rizatriptan benzoate equivalent to 14.3 mg rizatriptan benzoate. Labeler is A-S Medication Solutions in Libertyville, Illinois. Storage instructions specified at 68 to 77 degrees Fahrenheit.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of rizatriptan benzoate, the active ingredient in RIZAFILM 10 mg oral film by A-S Medication Solutions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.